These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33618254)

  • 1. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
    Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
    J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
    Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
    J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
    Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
    Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
    J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
    O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
    J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer.
    Dai R; Bao X; Liu C; Yin X; Zhu Z; Zheng Z; Wang B; Yang K; Wen H; Li W; Zhu H; Du Q; Liu J
    Eur J Med Chem; 2024 Dec; 279():116894. PubMed ID: 39357315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.
    Zhang B; Kiefer JR; Blake RA; Chang JH; Hartman S; Ingalla ER; Kleinheinz T; Mody V; Nannini M; Ortwine DF; Ran Y; Sambrone A; Sampath D; Vinogradova M; Zhong Y; Nwachukwu JC; Nettles KW; Lai T; Liao J; Zheng X; Chen H; Wang X; Liang J
    Bioorg Med Chem Lett; 2019 Apr; 29(7):905-911. PubMed ID: 30732944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
    Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
    Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
    Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
    Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
    Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
    J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
    Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
    J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
    Hu B; Hu J
    Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.